Zydus Cadila Receives FDA Approval for Marketing Pioglitazone in US

Zydus Cadila revealed that it has received the final approval from the USFDA to market its anti-diabetic drug.

Indian pharmaceutical firm Zydus Cadila revealed that it has received the final approval from the US Food and Drug Administration to market its anti-diabetic drug, Pioglitazone HCI, in the American market.

Zydus announced that it has received approval to market Pioglitazone HCI tablets in 15 mg, 30 mg and 45 mg strengths. The company added that sales for Pioglitazone HCI tablets was estimated at $2 billion in 2012, according to data from IMS.

Diabetes Essentials: Types, Complications, Management & Treatment
Diabetes is a metabolic disease caused by insulin deficiency that leads to high blood sugar levels and several associated complications if left untreated.

The company has so far filed over 170 Abbreviated New Drug Applications (ANDA) since 2003-04 and has so far received 75 approvals, including for the sale of oral tablets of Ultracet.

Source-Medindia

Diabetes Foot Care Treatment Prevention
Valuable information on diabetic foot care, treatment and prevention.

Diabetes Diet Plan
Diet plays a significant role in controlling diabetes. Most cases of diabetes are preventable with healthy lifestyle changes.

Diabetes and Exercise
Regular exercise especially in type II diabetes not only helps reduce the sugar but also reduces the demand for medication by 20% and helps you stay healthy.